Biotech · Private company
Kailera
Track this companyFree. Adds Kailera to your Dealase workspace and tells you when its record changes.
Clinical trials97 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- RibupatidePhase 3 · Obesity With DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- RibupatidePhase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SemaglutidePhase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- KAI-7535Phase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- KAI-4729Phase 1 · Overweight or ObesityClinicalTrials.gov · fetched Nov 12, 2026
- KAI-9531Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- RibupatidePhase 1 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or OverweightPHASE1 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07924761 · fetched Nov 12, 2026
- A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatidePHASE1 · RECRUITING · started Sep 8, 2026ClinicalTrials.gov NCT07793929 · fetched Nov 12, 2026
- Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 6, 2026ClinicalTrials.gov NCT07497880 · fetched Nov 12, 2026
- Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 4, 2026ClinicalTrials.gov NCT07458269 · fetched Nov 12, 2026
- Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 12, 2026ClinicalTrials.gov NCT07284901 · fetched Nov 12, 2026
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 30, 2025ClinicalTrials.gov NCT07284979 · fetched Nov 12, 2026
- Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 18, 2025ClinicalTrials.gov NCT07284875 · fetched Nov 12, 2026
- A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or OverweightPHASE1 · COMPLETED · started Dec 15, 2025ClinicalTrials.gov NCT07294898 · fetched Nov 12, 2026
- A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass IndicesPHASE1 · COMPLETED · started Jul 14, 2025ClinicalTrials.gov NCT07044401 · fetched Nov 12, 2026